The influence of antibody CD166 on the treatment of tumor and the immunological mechanism in mice bearing oral squamous cell carcinoma.

Background: This study aimed to investigate the influence of antibody CD166 on the inhibition of tumor and further investigate the influence on immune cells of tumor tissues in mice bearing oral squamous cell carcinoma (OSCC).
Methods: The xenograft model was established through subcutaneously injection of mouse OSCCs cells. Ten mice were randomly divided into two groups. The treatment group was treated with antibody CD166 and the control group was injected with the same volume normal saline. Hematoxylin and eosin (H&E) was used to confirm the tissue histopathology of xenograft mice model. Flow cytometry was used to detect the proportion of CD3 ⁺ CD8 ⁺ T cells, CD8 ⁺ PD-1 ⁺ cells and CD11b ⁺ Gr-1 ⁺ myeloid-derived suppressor cells (MDSCs) cells in the tumor tissues.
Results: After treatment with antibody CD166, the tumor volume and weight in xenograft mice model were significantly reduced. The result of flow cytometry showed that antibody CD166 showed no obvious influence on the proportion of CD3 ⁺ CD8 ⁺ and CD8 ⁺ PD-1 ⁺ T lymphocyte cells in the tumor tissues. In the antibody CD166 treatment group, the proportion of CD11b ⁺ Gr-1 ⁺ MDSCs cells in tumor tissues was 1.930%±0.5317%, which was significantly lower than that of the control group, 4.940%±0.3252% (P=0.0013).
Conclusions: Antibody CD166 treatment helped reduce the proportion of CD11b ⁺ Gr-1 ⁺ MDSCs cells, and produced obvious therapeutic effect on the treatment of mice bearing OSCC.
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-2704/coif). The authors have no conflicts of interest to declare.
(2023 Translational Cancer Research. All rights reserved.)